Cancer

[Abstract] Interaction of BRCA1 vs BRCA2 pathogenic variants with primary tumor location in pancreatic cancer

Background: BRCA1/2 germline or somatic pathogenic variants (PVs) are found in 5-10% of pancreatic adenocarcinoma (PDAC) patients. …

Ryan Hood, Nicholas J. Seewald, Srishti Rathore, Kim Anna Reiss

Prospective Assessment of Patient-Reported Outcomes and Estradiol and Drug Concentrations in Patients Experiencing Toxicity from Adjuvant Aromatase Inhibitors

Purpose. Aromatase inhibitors (AI), which decrease circulating estradiol concentrations in post-menopausal women, are associated with …

Kunal C. Kadakia, Kelley M. Kidwell, Nicholas J. Seewald, Claire F. Snyder, Anna Maria Storniolo, Julie L. Otte, David A. Flockhart, Daniel F. Hayes, Vered Stearns, N. Lynn Henry

Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women with Early Stage Breast Cancer

BACKGROUND. Early discontinuation of aromatase inhibitors (AIs) is common and leads to poor outcomes but is challenging to predict. In …

Kunal C. Kadakia, Claire F. Snyder, Kelley M. Kidwell, Nicholas J. Seewald, David A. Flockhart, Todd C. Skaar, Zereunesay Desta, James M. Rae, Julie L. Otte, Janet S. Carpenter, Anna M. Storniolo, Daniel F. Hayes, Vered Stearns, N. Lynn Henry

[Abstract] CYP3A4*22 polymorphism is associated with increased exemestane concentrations in postmenopausal breast cancer patients

Background: Exemestane is a second generation steroidal aromatase inhibitor (AI) used for the treatment of estrogen receptor (ER) …

Daniel L. Hertz, Kelley M. Kidwell, Nicholas J. Seewald, Christina L. Gersch, Zeruesenay Desta, David A. Flockhart, Ana-Maria Storniolo, Vered Stearns, Todd C. Skaar, Daniel F. Hayes, N. Lynn Henry, James M. Rae"

[Abstract] Crossover from One Aromatase Inhibitor (AI) to Another in the Exemestane and Letrozole Pharmacogenetics (ELPh) Trial

Background: Tolerance of AI therapy can be poor due to treatment-emergent toxicities and can lead to early discontinuation …

Kunal C. Kadakia, Kelley M. Kidwell, Nicholas J. Seewald, Claire Frances Snyder, David A. Flockhart, Janet S. Carpenter, Julie L. Otte, Daniel F. Hayes, Anna Maria Storniolo, Vered Sterns, Norah Lynn Henry

Evidence for Association of SNPs in ABCB1 and CBR3, but Not RAC2, NCF4, SLC28A3 or TOP2B, with Chronic Cardiotoxicity in a Cohort of Breast Cancer Patients Treated with Anthracyclines

AIMS: Validation of associations for SNPs in RAC2, NCF4 and SLC28A3, identification of a novel association with a TOP2B SNP and …

Daniel L. Hertz, Megan v. Caram, Kelley M. Kidwell, Jacklyn N. Thibert, Christina Gersch, Nicholas J. Seewald, Jeffrey Smerage, Melvyn Rubenfire, N. Lynn Henry, Kathleen A. Cooney, Monika Leja, Jennifer J. Griggs, James M. Rae

Polymorphisms in Drug-Metabolizing Enzymes and Steady-State Exemestane Concentration in Postmenopausal Patients with Breast Cancer

Discovery of clinical and genetic predictors of exemestane pharmacokinetics was attempted in 246 postmenopausal patients with breast …

[Abstract] Associations between treatment-emergent symptoms and early discontinuation of aromatase inhibitor (AI) therapy

ASCO Meeting Abstract from the 2015 ASCO Annual Meeting I

Kunal C. Kadakia, Claire Frances Snyder, Kelley M Kidwell, Nicholas J. Seewald, Anna Maria Storniolo, David A. Flockhart, Janet S. Carpenter, Daniel F. Hayes, Vered Stearns, Norah Lynn Henry

[Abstract] Primary CNS Lymphoma; A Review of the University of Michigan Experience 2004-2013

Background: Evidence supports high dose methotrexate (HD-MTX), rituximab, and cytarabine treatment for newly diagnosed primary CNS …

Aaron G. Mammoser, Shaio-Pei S. Weathers, Nicholas J. Seewald, Jeremy M. G. Taylor, Larry Junck